Haemonetics Corporation (HAE)
NYSE · Healthcare · Medical Devices
$104.680.00%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $4.8B
- P/E (trailing)
- 50.6
- Forward P/E
- 18.1
- 52-week range
- $48.17 – $110.45
- 52-week change
- +112.51%
- EPS (trailing)
- $2.07
- Analyst rating
- 1.7 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Mar 2026
- Revenue
- $1.3B (−1.97%)
- Net income
- $97K
- Operating margin
- 11.7%
- Diluted EPS
- $2.05
- Free cash flow
- $260M
From the company’s annual report on SEC EDGAR.
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications.
Headquarters: Boston, United States · 3,009 employees · haemonetics.com